title: [Viral infection risk in polytransfused adults: seroprevalence of seven viruses in central Tunisia].
abstract: The aim of this study is to evaluate the prevalence of seven transfusion-transmitted viruses in polytransfused adults and children comparatively with a group of healthy control subjects. We studied 107 polytransfused patients (59 adults and 48 children) and 160 control subjects (100 blood donors and 60 children). Immunoenzymatic tests were used for detection of HBs antigen (HBs Ag), antibodies against hepatitis C Virus (anti-HCV), and human immunodeficiency virus (anti-HIV), and IgG antibodies against human cytomegalovirus (IgG anti-CMV), human parvovirus B19 (IgG anti-PB19), and hepatitis E virus (IgG anti-HEV). An immunofluorescent assay was performed for the detection of human herpesvirus 8 antibodies (anti-HHV8). Prevalence of HBs Ag, anti-HCV, anti-HIV, IgG anti-CMV, IgG anti-PB19, IgG anti-HEV, and anti-HHV8 in polytransfused group was 8.4, 4.7, 0, 86.9, 60.7, 28.9, and 47.6%, respectively, and 1.8, 0.6, 0, 86.2, 53.1, 10, and 12.5%, respectively, in the control group. The difference in prevalence between the two groups was statistically significant for HBs Ag (P = 0.01), anti-HCV (P = 0.03), IgG anti-HEV (P < 10(-4)), and IgG anti-HHV8 (P < 10(-4)). Categorization according to age showed that hepatitis B and C risk was limited in adult polytransfused group. HHV8 infection was higher in polytransfused subjects born before the use of leucocyte-depleted blood components. Our results corroborate literature data on the risk of HEV and HHV8 infection by blood transfusion. Hepatitis B vaccination and improvement in screening tests have an important role in reduction of hepatitis B and C risk in transfusion, especially in young polytransfused persons. However, a residual risk of transmitting viral infections persists, and efforts are needed to improve transfusion safety.
authors.affiliation: Laboratoire de microbiologie-immunologie, UR02SP13, CHU Farhat-Hached, Sousse, Tunisie. nhannachi@lycos.com
authors.forename: N
authors.initials: N
authors.lastname: Hannachi
authors.forename: L
authors.initials: L
authors.lastname: Boughammoura
authors.forename: M
authors.initials: M
authors.lastname: Marzouk
authors.forename: M
authors.initials: M
authors.lastname: Tfifha
authors.forename: A
authors.initials: A
authors.lastname: Khlif
authors.forename: S
authors.initials: S
authors.lastname: Soussi
authors.forename: H
authors.initials: H
authors.lastname: Skouri
authors.forename: J
authors.initials: J
authors.lastname: Boukadida
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000914:Antibodies, Viral / Q000097:blood; D001782:Blood Donors; D002648:Child; D002675:Child, Preschool; D005260:Female; D015658:HIV Infections / Q000097:blood / Q000453:epidemiology* / Q000635:transmission; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000453:epidemiology* / Q000635:transmission; D006566:Herpesviridae Infections / Q000097:blood / Q000453:epidemiology* / Q000635:transmission; D006801:Humans; D016867:Immunocompromised Host; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D007223:Infant; D008297:Male; D008875:Middle Aged; D010322:Parvoviridae Infections / Q000097:blood / Q000453:epidemiology* / Q000635:transmission; D016732:Parvovirus B19, Human / Q000276:immunology; D012306:Risk; D016036:Seroepidemiologic Studies; D065227:Transfusion Reaction; D014416:Tunisia / Q000453:epidemiology; D055815:Young Adult
chemical_list: D000914:Antibodies, Viral; D007074:Immunoglobulin G; D007075:Immunoglobulin M